# Phase 1 Head and Neck Neoplasms trials recruiting: 43 (2026)

Updated November 19, 2026.

ClinicalTrials.gov lists 43 trials in phase 1 for Head and Neck Neoplasms that are recruiting or not yet recruiting, as read on November 19, 2026.

## The full list

Recruiting Phase 1 Head and Neck Neoplasms trials: 43 rows for $5, recruiting or not yet recruiting on ClinicalTrials.gov as read on November 19, 2026. Columns: NCT ID, Title, Sponsor, Sponsor class, Phase, Status, Conditions, Condition groups (MeSH), Interventions, Start date, First posted, Last update posted, Enrollment, Location countries, Read on, Source. The new rows each week by email, about 2 rows a month: $19 a month. Pay by card with no account. Prices exclude VAT. CSV and Excel files with the columns this page does not show (sponsor class, condition groups (MeSH), interventions, start date, last update posted and location countries), which open on your screen as soon as the payment clears and come by email. The rows on this page are a sample.

Buy: https://specstream.ai/data/clinical-trials/recruiting/phase-1/head-and-neck-neoplasms

SpecStream is the live web data engine for teams and agents. It reads ClinicalTrials.gov each morning, and this page is that reading. Ask for the sponsors, conditions, phases or places you follow and each new or changed trial arrives in your sheet, CRM, Slack or agent with the sponsor, phase, status and sites.

- Trials: 43
- Recruiting or not yet: 43
- Read on: November 19, 2026

## Trials

The 25 newest of 43, each linked to its ClinicalTrials.gov record. The full list holds every one.

| First posted | NCT ID | Title | Sponsor | Phase | Status | Conditions | Enrollment | Source |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| October 28, 2026 | NCT07901959 | Safety and Tolerability of Metformin and Naproxen for Cancer Prevention in Fanconi Anemia | Rockefeller University | Phase 1 | Recruiting | Fanconi Anemia, Head and Neck Cancer, Squamous Cell Carcinoma, Squamous Cell Cancer of Head and Neck (SCCHN) | 80 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07901959) |
| October 5, 2026 | NCT07856732 | Using Silverlon® for Head and Neck Patients With Tracheostomies | State University of New York - Upstate Medical University | Phase 1 | Recruiting | Head and Neck Cancer, Radiation Dermatitis Acute, Radiation Treatment | 10 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07856732) |
| September 10, 2026 | NCT07814248 | A Phase 1, First-in-Human (FIH), Open-Label, Dose-Escalation and Dose Expansion Study of the Peptide Drug Conjugate (PDC), TS-104, as a... | TwoStep Therapeutics, Inc. | Phase 1 | Recruiting | NSCLC (Non-small Cell Lung Cancer), HNSCC, Endometrial, Ovarian Cancer, Esophageal Cancer, Head & Neck Cancer, Gastric... | 74 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07814248) |
| August 13, 2026 | NCT07763639 | A Study of SI-B036 in Patients With Locally Advanced or Metastatic Head and Neck Tumors and Other Solid Tumors | Sichuan Baili Pharmaceutical Co., Ltd. | Phase 1 | Recruiting | Head and Neck Tumors, Solid Tumors | 30 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07763639) |
| August 3, 2026 | NCT07741643 | Study Evaluating the Safety and Feasibility of Panitumumab-IRDye800 and \[18F\]NOTA-ABY-030 for Targeted Dual-Modality Imaging (TDMI) in Head... | Vanderbilt-Ingram Cancer Center | Phase 1 | Recruiting | HNSCC,Larynx, Pharynx and Oral Cavity, Squamous Cell Carcinoma, Head and Neck Cancer, Head and Neck Surgery | 30 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07741643) |
| July 8, 2026 | NCT07690618 | Thermotherapy for Head and Neck Cancer Patients | Erasmus Medical Center | Phase 1 | Recruiting | Head and Neck Cancer, Oropharyngeal Carcinoma, Hypopharyngeal Carcinoma, Laryngeal Carcinoma, Head and Neck Squamous... | 30 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07690618) |
| June 9, 2026 | NCT07635277 | Akkermansia Muciniphila (AKK) for Radiation-Induced Skin Injury | West China Hospital | Phase 1 | Recruiting | Radiation-Induced Skin Injury | 40 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07635277) |
| June 4, 2026 | NCT07625423 | Intratumoral Injection of Recombinant Human Endostatin Adenovirus (EDS01) for the Treatment of Recurrent or Metastatic Head and Neck Tumors | West China Hospital | Phase 1 | Recruiting | Head & Neck Cancer, Nasopharyngeal Cancinoma (NPC) | 9 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07625423) |
| May 29, 2026 | NCT07613723 | A Study to Test the Safety, Tolerability and Effect of ZI-MA4-1 for Patients With Locally Advanced or Metastatic Solid Malignancies | Sponsor not shown (see the record) | Phase 1 | Recruiting | Ovarian Cancer, Squamous Non-Small Cell Lung Cancer (NSCLC), Synovial Sarcomas, Head and Neck Cancer | 9 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07613723) |
| May 13, 2026 | NCT07583914 | Safety, Tolerability, and Preliminary Antitumor Activity of Non-Cationic Peptide-CD47 siRNA in Advanced Solid Tumors | West China Hospital | Phase 1 | Not yet recruiting | Solid Tumor Cancer, Metastases, Head and Neck Cancer | 9 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07583914) |
| May 13, 2026 | NCT07583316 | A Phase 1 First-in-Human Study of CRPA1A2, a MAGE-A1/HLA-A\*02:01 Bispecific T-Cell Engager, in Patients With Solid Tumors | Corregene Biotechnology Co., Ltd | Phase 1 | Not yet recruiting | Lung Cancer (Locally Advanced or Metastatic), Esophagus Cancer, Head and Neck Cancer, Hepatocellular Carcinoma (HCC) | 192 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07583316) |
| March 30, 2026 | NCT07501650 | Pembrolizumab Plus Ultrasound-Induced Microbubble Cavitation in Head and Neck Cancer | Thomas Jefferson University | Phase 1 | Recruiting | Head and Neck Cancer, Head and Neck Small Cell Carcinoma, Metastatic Head and Neck Cancer, Recurrent Head and Neck... | 6 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07501650) |
| March 10, 2026 | NCT07462377 | A Phase 1 Study of EPI-326 in EGFR-mutant NSCLC and HNSCC | EpiBiologics | Phase 1 | Recruiting | Epidermal Growth Factor, Epidermal Growth Factor Receptor, Epidermal Growth Factor Receptor Gene Mutation, Non Small... | 110 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07462377) |
| March 10, 2026 | NCT07460765 | Safety and Feasibility of Nivolumab-IRDye800CW in Patients With Head and Neck Squamous Cell Carcinoma (HNSCC) | Vanderbilt-Ingram Cancer Center | Phase 1 | Recruiting | Hnscc, Head and Neck, Squamous Cell Cancer, Squamous Carcinoma, Squamous Cell Cancer of Head and Neck (SCCHN), Squamous... | 40 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07460765) |
| January 22, 2026 | NCT07358806 | Study to Assess the Effect of OCT-598 in Patients With Advanced Solid Tumors | Oscotec Inc. | Phase 1 | Recruiting | Solid Tumor, Breast Cancer, Head and Neck Cancer, Non-Small Cell Lung Cancer, Prostate Cancer, Gastric/Gastroesophageal... | 51 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07358806) |
| September 4, 2025 | NCT07154108 | Endostatin Adenovirus With Checkpoint Inhibitor in Advanced Head and Neck or Esophageal Cancer | Sichuan University | Phase 1 | Not yet recruiting | Esophageal Cancer, Head and Neck Cancer (H&Amp;Amp;Amp;N) | 40 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07154108) |
| August 3, 2025 | NCT07101432 | Phase I Study of Preconditioning Radiation Therapy With IL-15 Transduced TGFBR2 KO CAR.TROP2-engineered Cord Blood-derived NK Cells in... | M.D. Anderson Cancer Center | Phase 1 | Recruiting | Head and Neck Cancer | 33 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07101432) |
| July 29, 2025 | NCT07090499 | A Study to Learn About the Study Medicine Called PF-08046876 in People With Advanced Solid Tumors | Pfizer | Phase 1 | Recruiting | Advanced/Metastatic Solid Tumors, Bladder Cancer, Urothelial Carcinoma, Advanced Non-Small Cell Lung Cancer, Carcinoma... | 540 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07090499) |
| July 25, 2025 | NCT07085091 | A First in Human Study of ALX2004 With Advanced or Metastatic Selected Solid Tumors | ALX Oncology Inc. | Phase 1 | Recruiting | NSCLC (Advanced Non-small Cell Lung Cancer), HNSCC, CRC (Colorectal Cancer), ESCC, Colo-rectal Cancer, Head and Neck... | 170 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07085091) |
| July 18, 2025 | NCT07072325 | Safety, Tolerability, PK, and Efficacy of CD-001 in Advanced Head & Neck Cancers | West China Hospital | Phase 1 | Not yet recruiting | Malignant Neoplasm, Head &Amp; Neck Cancer, Head and Neck Cancer, Advanced Head and Neck Carcinoma | 9 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07072325) |
| June 13, 2025 | NCT07020117 | A Study of \[225Ac\]Ac-AKY-1189 in Patients With Solid Tumors | Aktis Oncology, Inc. | Phase 1 | Recruiting | Urothelial Carcinoma Bladder, Triple Negative Breast Cancer (TNBC), Hormone Receptor Positive Breast Adenocarcinoma... | 150 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07020117) |
| April 4, 2025 | NCT06912087 | Dose Finding Study of Zanzalintinib With Pembrolizumab and Cetuximab in Head and Neck SCC | University of Chicago | Phase 1 | Recruiting | Head and Neck Neoplasms, Carcinoma, Squamous Cell, Neoplasm Recurrence, Local, Neoplasm Metastasis, Recurrent Squamous... | 36 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06912087) |
| April 4, 2025 | NCT06910657 | IDOV-Immune for Advanced Solid Tumors | ViroMissile, Inc. | Phase 1 | Recruiting | Colorectal Cancer, Pancreatic Cancer, Melanoma, Ovarian Cancer, Gastric Cancer, Esophageal Cancer, Hepatocellular... | 78 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06910657) |
| February 11, 2025 | NCT06819228 | Window Trial of Fluorescently Labeled Panitumumab (Panitumumab-IRDye800) in Head and Neck Cancer | Vanderbilt-Ingram Cancer Center | Phase 1 | Recruiting | HNSCC, HNSCC,Larynx, Pharynx and Oral Cavity, SCC - Squamous Cell Carcinoma | 70 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06819228) |
| December 16, 2024 | NCT06736379 | Intratumoral Delivery of Viral Replicon (saRNA) Particles Expressing IL-12 in Head and Neck Cancer | VLP Therapeutics | Phase 1 | Recruiting | Head and Neck Cancers- Squamous Cell, Head and Neck Cancer, Solid Tumors, HNSCC, SCC - Squamous Cell Carcinoma, SCCHN... | 41 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06736379) |

## Sponsors with the most

| Sponsor | Trials |
| --- | --- |
| West China Hospital | 4 |
| Vanderbilt-Ingram Cancer Center | 3 |
| [Sichuan Baili Pharmaceutical Co., Ltd.](https://specstream.ai/data/clinical-trials/company/sichuan-baili-pharmaceutical-co-ltd) | 2 |
| University of Chicago | 2 |
| University Medical Center Groningen | 2 |
| Corregene Biotechnology Co., Ltd | 2 |
| ALX Oncology Inc. | 1 |
| [Pfizer](https://specstream.ai/data/clinical-trials/company/pfizer) | 1 |
| Memorial Sloan Kettering Cancer Center | 1 |
| TwoStep Therapeutics, Inc. | 1 |
| Rockefeller University | 1 |
| Mabpro, a.s. | 1 |
| UNC Lineberger Comprehensive Cancer Center | 1 |
| ViroMissile, Inc. | 1 |
| Bicara Therapeutics | 1 |
| VLP Therapeutics | 1 |
| Memgen, Inc. | 1 |
| The Affiliated Hospital of Qingdao University | 1 |
| Sichuan University | 1 |
| National Cancer Institute (NCI) | 1 |
| State University of New York - Upstate Medical University | 1 |
| M.D. Anderson Cancer Center | 1 |
| Aktis Oncology, Inc. | 1 |
| BlueSky Immunotherapies GmbH | 1 |
| EpiBiologics | 1 |

## By country

| Country | Trials |
| --- | --- |
| United States | 23 |
| China | 9 |
| Netherlands | 3 |
| Canada | 2 |
| United Kingdom | 2 |
| Australia | 2 |
| South Korea | 2 |
| Puerto Rico | 1 |
| Spain | 1 |
| Austria | 1 |
| Taiwan | 1 |
| Japan | 1 |

## Where the register publishes

- [ClinicalTrials.gov](https://clinicaltrials.gov/)
- [ClinicalTrials.gov API](https://clinicaltrials.gov/data-api/api)

Source: [ClinicalTrials.gov API v2 (U.S. National Library of Medicine)](https://clinicaltrials.gov/data-api/api). U.S. government data; ClinicalTrials.gov terms of use. Studies are as their sponsors registered them on ClinicalTrials.gov, read through its API. Recruiting means the record's overall status is recruiting or not yet recruiting. Condition groups are the MeSH terms ClinicalTrials.gov assigns; a condition page also counts the narrower terms that name it, as the register's own search does (triple negative breast neoplasms are breast neoplasms). Sites are shown as organizations only; no investigator or contact is read or shown.

Free to quote with credit and a link. Copying in bulk needs a [data licence](https://specstream.ai/data/licence).

## Business lists in the United States

- [Afghani restaurants in the United States](https://specstream.ai/data/businesses/afghani-restaurants/united-states)
- [B2B international trade companies in the United States](https://specstream.ai/data/businesses/b2b-international-trade-companies/united-states)
- [Breweries in the United States](https://specstream.ai/data/businesses/breweries/united-states)
- [Clothing companies in the United States](https://specstream.ai/data/businesses/clothing-companies/united-states)
- [Divorce and family law firms in the United States](https://specstream.ai/data/businesses/divorce-and-family-law-firms/united-states)
- [Exporters in the United States](https://specstream.ai/data/businesses/exporters/united-states)
